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November 20111544 AbstractsConclusion: We hypothesized that a diagnosis of malignancy would
predispose patients to failure after peripheral endovascular intervention.
Surprisingly, patients with a history of malignancy showed equivalent pa-
tency to controls at 3 years post-intervention. To our knowledge, this is the
first study to show that the hypercoagulable state associated withmalignancy
is not an independent predictor of failure after peripheral endovascular
arterial intervention. Hence, a diagnosis of cancer should not preclude
endovascular interventions in symptomatic patients.
Hazard ratio
(95% Cl) P value
Primary patency
Diabetes mellitus 1.23 (1.06-1.43) .006
Chronic renal insufficiency 1.13 (.97-1.3) .097
Smoking 1.36 (1.11-1.67) .003
Critical limb Ischemia 2.28 (1.96-2.66) .001
Cancer .882 (.723-1.076) .215
Primary Assisted patency
Diabetes mellitus 1.35 (1.12-1.63) .002
Chronic renal insufficiency 1.29 (1.08-1.54) .004
Current Smoking 1.54 (1.21-1.96) .001
Critical limb Ischemia 3.52 (2.86-4.33) .001
Cancer .824 (.638-1.06) .135
Secondary patency
Diabetes mellitus 1.42 (1.15-1.76) .001
Chronic renel insufficiency 1.30 (1.07-1.58) .007
Current Smoking 1.58 (1.21-2.05) .001
Critical limb Ischemia 4.1 (3.2-5.3) .001
Cancer .837 (.633-1.10) .211
Limb Salvage
Diabetes mellitus 2.58 (1.48-4.48) .001
Chronic renal insufficiency 1.29 (.846-1.98) .234
Current Smoking 2.29 (1.38-3.81) .001
Cancer .706 (.355-1.40) .323
A Novel Mechanism for TGF-beta/Smad3 in the Development of
Intimal Hyperplasia
Pasithorn Amy Suwanabol, MD, Stephen Seelial, BS, Daniel Shi, MD, PhD,
Fan Zhang, MD, PhD, Dai Yamanouchi, MD, PhD, Bo Liu, PhD, K. Craig
Kent, MD, University of Wisconsin, Madison, Wisc
Objectives: Intimal hyperplasia (IH) is defined as vascular smooth
muscle cell (VSMC) proliferation and is mediated by a number of cytokines
including TGF-. Our laboratory has previously demonstrated that TGF-’s
primary signaling pathway, Smad3, enhances VSMC proliferation and IH.
However, the exact mechanism by which Smad3 increases IH has yet to be
fully elucidated. We hypothesize that Smad3 mediates activation of ERK
MAPK through phosphorylation to increase VSMC proliferation thereby
increasing IH.
Methods:Cultured VSMC were infected with adenovirus expressing
Smad3 (AdSmad3) or control virus (AdGFP) and treated with TGF-.
VSMC were transfected with siRNA to Smad3 or scramble siRNA
(control) followed by stimulation with TGF-. Cell lysate was collected
for Western blot analysis or immunoprecipitation for proteins that com-
plex with Smad3 and immunoblotted by using p-ERK antibody. VSMC
were infected with AdSmad3 or AdGFP followed by pretreatment with
ERK inhibitor (PD 98059) then TGF-. Cell proliferation was deter-
mined by MTT assay. Male Sprague-Dawley rats underwent left carotid
balloon injury followed by intraluminal infection with AdSmad3 or
AdGFP. P-ERK and proliferating cell nuclear antigen (PCNA) were
evaluated by immunohistochemisty.
Results: TGF- increased expression of p-ERK at one hour in a
dose-dependent fashion.When compared to control-treated VSMC, TGF-
and Smad3 increased p-ERK expression by two-fold (p  0.05). Addition-
ally, siRNA to Smad3 decreased TGF--induced p-ERK expression by over
two-fold (p  0.05). The involvement of ERK in cell proliferation was
evaluated by pretreating VSMC with PD 98059 which decreased TGF-/
Smad3-induced cell proliferation by over two-fold (p 0.05). Immunopre-
cipitation demonstrated that Smad3 complexes with ERK in VSMC stimu-
lated with TGF-. In balloon-injured carotid arteries, treatment with
AdSmad3 (n  3) demonstrate enhanced p-ERK and PNCA when com-
pared to arteries treated with AdGFP (n  3, p  0.05).
Conclusions:We demonstrate that TGF--induced activation of ERK
is at least partially Smad3-dependent. We have shown that TGF-/Smad3
increases vascular smooth cell proliferation and this is mediated by ERK
MAPK activation. Inhibiting these components of the TGF-/Smad3 sig-
naling pathway may prevent the development of restenosis.
m
iccelerated Aneurysmal Dilatation Associated with Apoptosis and
nflammation in a Newly Created Modified Calcium Chloride Rodent
AA Model
ai Yamanouchi, MD, Stephanie Morgan, Colin Stair, Stephen Seedial,
ustin Lengfeld, K. Craig Kent, MD, Bo Liu, PhD, University of Wisconsin
chool of Medicine and Public Health, Madison, Wisc
Objective: The Calcium Chloride (CaCl2) model is a widely accepted
odent model for abdominal aortic aneurysm (AAA). Calcium deposition,
ainly consisting of calcium phosphate (CaPO4) crystals, has been reported
o exist in both human and experimental aneurysms. CaPO4 crystal has been
tilized for in vitro DNA transfection by mixing CaCl2 and Phosphate
uffered Saline (PBS). Here, we describe accelerated aneurysm formation
esulting from a modification of the CaCl2 model.
Methods: The modified CaCl2 model was created by applying PBS
nto the mouse infrarenal aorta after CaCl2 treatment. Morphological,
istological and immunohistochemical analysis were performed onmodified
aCl2 model and the conventional CaCl2 model as control. In vitro meth-
ds were carried out using a mixture of CaCl2 and PBS to create CaPO4
rystals. CaPO4 induced apoptosis of primary cultured mouse vascular
moothmuscle cells (VSMCs) wasmeasured byDNA fragmentation ELISA.
Results: First, we showed that the modified CaCl2 model produces
AA, defined as an increase of 50% or greater in the diameter of the aorta;
aster than in the CaCl2 model (Fig, A and B). Modified CaCl2 model
howed significantly larger aneurysmal dilation at 7, 28 and 42 days as
eflected by a maximum diameter fold change of 1.69  0.07, 1.99  0.14
nd 2.13  0.09 as opposed to 1.22  0.04, 1.48  0.07 and 1.68  0.06
s seen in CaCl2 model, respectively (n 6; P .05). Histological analyses
t 7 days reveal a significant increase in elastin degradation inmodifiedCaCl2
odel (Fig, C). Significantly higher level of apoptosis occurred in the
odified CaCl2 model (apoptosis index at 1, 2, and 3 days post-surgery:
.26  0.14, 0.37 0.14, and 0.33  0.08 for modified CaCl2 model and
.012 0.10, 0.15 0.02, and 0.12 0.05 for conventional CaCl2model)
n  3; P  .05). An enhancement of macrophage infiltration and calcifica-
ion was also observed at 3 and 7 days in modified CaCl2 model. CaPO4
nduced approximately 3.7 times more apoptosis in VSMCs when compared
o a mixture of CaCl2 and saline (n  4; P  .0001) in vitro.
Conclusion: Our data shows that the modified CaCl2 model acceler-
tes aneurysm formation with the enhancement of apoptosis, macrophage
nfiltration and calcium deposition. This modified model, with its rapid and
obust dilatation, can be utilized as a new model for AAA.
ndovascular Aortic Aneurysm Repair with Carbon Dioxide Guided
ngiography in Patients With Renal Insufficiency
nrique Criado, MD, Gilbert Upchurch, MD, John Rectenwald, MD, Kate
oung, RN, Dawn Coleman, MD, Jon Eliason, MD, Department of Sur-
ery, University of Michigan School of Medicine, Ann Arbor, Mich
Objectives: Renal dysfunction following endovascular abdominal aor-
ic aneurysm repair (EVAR) remains a source of morbidity andmortality.We
xamined the use of carbon dioxide (CO2) as a non-nephrotoxic contrast
gent for EVAR.
Methods: We analyzed prospectively recorded data from 114 consec-
tive patients who underwent EVARwith CO2 as the contrast agent over 44
Fig.onths. CO2 was used exclusively in 72 cases, and in 42, additional
odinated contrast (IC) was given (mean: 37 mLs.). Renal and hypogastric
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Volume 54, Number 5 Abstracts 1545artery localization, and completion angiography were done with CO2 in all
patients, including hypogastric embolization in 26 cases. Preoperative na-
tional kidney foundation (NKF) glomerular filtration rate (GFR) classifica-
tion was: normal in 16 patients, mildly decreased in 52, moderate to severely
decreased in 44, and 2 were in renal failure.
Results: All grafts were successfully deployed with no conversions.
CO2 angiography identified 20 endoleaks (2 type 1, 16 type 2 and 2 type 4)
and 3 unintentionally covered arteries. Additional use of IC in 42 patients
did not modify the procedure in any case. When compared with a cohort of
50 consecutive patients who underwent EVAR done exclusively with IC, the
operative time was shorter with CO2 (177 vs 194min; P .01); fluoroscopy
time was less (21 vs 28min; P .002), and volume of iodinated contrast was
lower (37 vs 106 mLs; P .001). Postoperatively, there was one death, one
instance of renal failure, and no complications related to CO2 use. Patients
with moderate to severely decreased GFR undergoing EVAR with IC had a
12.7% greater (P  .004) decrease in GFR compared with the CO2 EVAR
group. At one, six and 12 month follow-up, CTAs showed well positioned
endografts with the expected patent renal and hypogastric arteries in all
patients, and no difference in endoleak detection compared with the iodin-
ated contrast EVAR group. During follow-up, 8 transluminal interventions
and one open conversion were required, but no aneurysm related deaths
occurred.
Conclusions: CO2 guided EVAR is technically feasible and safe, it
eliminates or reduces the need for iodinated contrast use, may expedite the
procedure, and avoids deterioration in renal function in patients with
pre-existing renal insufficiency. A prospective trial comparing CO2 with
iodinated contrast during EVAR is warranted.
Does a Regional Protocol for Ruptured Aortic Aneurysms Improve
Outcomes?
Alexander S. Tretinyak, MD, Christopher Solie, Adnan Z. Rizvi, MD, Peter
B. Alden, MD, Ross F. Garberich, John N. Graber, MD, Jason Q. Alexan-
der, MD, Timothy M. Sullivan, MD, Department of Vascular/Endovascu-
lar Surgery, Minneapolis Heart Institute at Abbott Northwestern Hospital,
Minneapolis, Minn
Objectives: Earlier diagnosis and shortened transfer times may im-
prove survival for ruptured aortic aneurysms (RAA). Endovascular aneurysm
repair (EVAR) requires specialized resources and planning prior to repair.
We analyzed the impact of a regional RAA specific protocol on time to
transfer, repair and survival at a large community based hospital.
Methods: A RAA protocol was developed to expedite evaluation,
transfer and treatment of RAAs, defined as retroperitoneal or free intra-
abdominal hemorrhage by CT scan. Educational visits were made and RAA
specific order sets were developed and distributed to referring and receiving
emergency departments (ED). A vascular surgeon evaluated each RAA in
our ED and assembled the appropriate team for EVAR or open repair. Data
collection began with the institution’s first EVAR for RAA,December 2006,
continuing prospectively to March 2011. Time from diagnosis to transfer,
arrival in our ED to treatment, and 30 day survival were primary endpoints.
Chi-squared or Fisher exact tests were used to compare categorical variables
and T-tests on log transformed values were used for continuous data.
Results: There were 13 control patients (62% EVAR) pre protocol and
31 patients (74% EVAR) following initiation of the protocol. There were 24
referring EDs; the furthest was 182 miles. Mean time from referring hospital
arrival to transfer decreased post protocol, (530 vs 261 min, P .44), as did
arrival at the referring hospital to treatment (601 vs 369 min, P  .32).
Thirty day survival improved from 69% to 85% (P  .161) post protocol.
Patients undergoing EVAR went from diagnosis to treatment more rapidly
post protocol (282 vs 215 min, P .49); open repair also improved (258 vs
101 min, P  .25). Fewer post protocol patients required post treatment
dialysis, 42% vs 7% (P  .006).
Conclusions: EVAR of RAA complements open surgery but requires a
compressed triage, decision, and planning period. A positive trend was
demonstrated using a defined regional protocol for RAA; times to diagnosis,
transfer, and treatment diminished, survival increased, and fewer patients
required dialysis. Given the small sample size, statistical significance was not
achieved.
The Hostile Landing Zone in Endograft Repair of the Thoracic Aorta:
The Next Frontier
Ali Shahriari, MD, James Williams, MD, Indiana Aortic Disease Institute,
Indianapolis, Ind
Objective: Thoracic endo-vascular repair of the aorta (TEVAR) is
gaining popularity in the treatment of thoracic aortic pathologies. One of the
limitations to the use of this treatment modality is unfavorable landing zone
(LZ) anatomy proximally and distally involving the aortic arch and visceral
branch vessels. We report our experience with extending the LZs using
endobranching and an on-table modified device design to offer a treatment
option to these high-risk patients.
A
(Methods: Between January 2009 and February 2011, 31 patients
nderwent TEVAR involving the supra-aortic or paravisceral branches.
ifteen patients (48%) were treated with adjunctive stenting of the supra-
ortic branches (“Snorkel” technique) and another 16 (52%) were treated
ith modified endovascular devices. Since January 2010 on-table modified
evices have been used in our institution to treat high-risk patients with
horacic and thoraco-abdominal aortic pathologies. Chart analysis was per-
ormed and data was collected. Endpoints were technical success, mortality,
aralysis, myocardial infarction, renal insufficiency, and branch vessel pa-
ency. The follow-up is 96.7%.
Results: There was 1 early and 2 late deaths (9.7%). The procedure
elated mortality was 0. The technical success for both techniques was 100%.
ne patient (3.2%) suffered acute on chronic renal insufficiency. One patient
3.2%) suffered an intraoperative stroke from a ruptured cerebral aneurysm.
ranch vessel patency for the patients treated with the snorkel technique was
3% and 100% for patients treated with the modified devices. There was one
ype I endoleak. The mean follow-up is 16 months.
Conclusion: Difficult LZ anatomy can be managed using both
he “snorkel” technique and modified devices. Currently these options
re offered to high-risk candidates. Detailed anatomical analysis and the
elationship of the branch vessels are imperative to the success of the
rocedure.
n Institutional Survey of the Use of Anti-Coagulation for Deep Vein
hromboses Below the Knee: What Is the Treatment Standard?
. Calloway Robertson, Ross Milner, MD, Vascular Surgery, Loyola Uni-
ersity Health System, Maywood, Ill
Objective: The ideal treatment for patients with deep vein thrombosis
DVT) below the knee remains undefined. Treatment recommendations
ange from conservative management to full-dose anti-coagulation. In our
tudy, we assessed practice patterns at a single institution for DVTs below
he knee.
Methods: Physicians were sent an email survey via Survey Monkey™
ith 8 multiple choice questions about management of DVT below
he knee. The questions addressed whether anti-coagulation was used;
he choices of anti-coagulation; use of follow-up duplex ultrasound; time
eriod before follow-up duplex ultrasound; the use of conservative
anagement; duration of anti-coagulation therapy; IVC filter use for
eep vein thrombosis below the knee; and the specialty of the physician.
he results were analyzed to compare current practices for treatment of
VT below the knee.
Results: A total of 99 physicians participated in the survey. Of these 99
articipants, 48 (48.5%) stated that they anti-coagulate patients with DVTs
elow the knee and 51 (51.5%) do not anti-coagulate. Of the 48 physicians
hat anti-coagulate, 62.3% use LMW heparin. IV heparin was used by 11%
nd anti-platelet agents were used by 7.5%. Of the 51 physicians who do not
nti-coagulate patients with DVT below the knee, 71.2% reassessed for clot
ropagation or resolution with a duplex exam. 48% obtain follow-up duplex
cans at 1 week, 37% at 2 weeks, and 11.1% at 1 month post-initial duplex
can. The length of anti-coagulation was 3 months for 58% of the 48
articipants who anti-coagulate patients and 30% anti-coagulate for 6
onths. IVC filters were used by 46% when there was a contraindication to
nti-coagulation and used by 13.7% when clot propagation was noted by
ollow-up duplex scan. 45.5% specialized in medicine, 11.1% surgery, 5.1%
eurosurgery, and 5.1% Ob/gyne.
Conclusions: These results suggest that there is no difference be-
ween the numbers of physicians anti-coagulating patients with DVT
elow the knee as compared to conservative management. There is
ubstantial variability in the medications used to anti-coagulate patients.
his institutional survey suggests that there is no standard practice for the
se of anti-coagulation for treatment of DVT below the knee. In addi-
ion, there is a higher than expected rate of IVC filters placed for DVT
elow the knee.
ffect of Antiplatelet Agents and Statins on Infrainguinal Bypass Graft
atency: Is There an Impact?
mar Al-Nouri, DO, Andrew Gassman, MD, Leah Phillippi, R. Hersh-
erger, P. Halandras, Ross Milner, MD, Bernadette Aulivola, MD, Loyola
niversity Medical Center, Maywood, Ill
Objective: We hypothesized medications that are commonly pre-
cribed for atherosclerosis influence infrainguinal bypass graft patency.
Methods: We retrospectively reviewed all infrainguinal bypasses per-
ormed at a single institution between January 2006 and December 2009.
e collected data on demographics, comorbidities, medications, graft char-
cteristics, graft patency, limb salvage, and mortality.
Results: We identified 112 patients who underwent 116 infrainguinal
ypasses during the study period. Mean age was 65 and 58% were men. Bypass
as performed for critical limb ischemia in 78% and claudication in 22%.
utologous vein was used in 37% and prosthetic grafts in 63%. Most grafts
65%) crossed the knee to distal targets. Coexisting diseases included hyperten-
